ATE501727T1 - Zusammensetzung zur immunisierung gegen mykobakterien - Google Patents

Zusammensetzung zur immunisierung gegen mykobakterien

Info

Publication number
ATE501727T1
ATE501727T1 AT06700223T AT06700223T ATE501727T1 AT E501727 T1 ATE501727 T1 AT E501727T1 AT 06700223 T AT06700223 T AT 06700223T AT 06700223 T AT06700223 T AT 06700223T AT E501727 T1 ATE501727 T1 AT E501727T1
Authority
AT
Austria
Prior art keywords
antigen
composition
immunization against
vector expressing
against mycobacteria
Prior art date
Application number
AT06700223T
Other languages
English (en)
Inventor
Helen Mcshane
Ansar A Pathan
Adrian Hill
Sarah C Gilbert
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Priority claimed from PCT/GB2006/000023 external-priority patent/WO2006072787A1/en
Application granted granted Critical
Publication of ATE501727T1 publication Critical patent/ATE501727T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Techniques For Improving Reliability Of Storages (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT06700223T 2005-01-05 2006-01-05 Zusammensetzung zur immunisierung gegen mykobakterien ATE501727T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0500102.9A GB0500102D0 (en) 2005-01-05 2005-01-05 Method for generating a memory t cell response
US64980405P 2005-02-03 2005-02-03
PCT/GB2006/000023 WO2006072787A1 (en) 2005-01-05 2006-01-05 Compositions for immunizing against mycobacterium

Publications (1)

Publication Number Publication Date
ATE501727T1 true ATE501727T1 (de) 2011-04-15

Family

ID=34179184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06700223T ATE501727T1 (de) 2005-01-05 2006-01-05 Zusammensetzung zur immunisierung gegen mykobakterien

Country Status (12)

Country Link
US (1) US7850979B2 (de)
CN (2) CN102580070A (de)
AT (1) ATE501727T1 (de)
DE (1) DE602006020679D1 (de)
DK (1) DK1833507T3 (de)
ES (1) ES2364698T3 (de)
GB (1) GB0500102D0 (de)
PT (1) PT1833507E (de)
RS (1) RS51815B (de)
SI (1) SI1833507T1 (de)
UA (1) UA93665C2 (de)
ZA (1) ZA200706389B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1144447T3 (da) 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
US20100226998A1 (en) * 2009-03-05 2010-09-09 Ultradent Products, Inc. Anti-viral and anti-microbial dental operative material and methods
MX344052B (es) * 2009-05-13 2016-12-02 Immport Therapeutics Inc Composiciones y metodos para antigenos inmunodominantes de mycobacterium tuberculosis.
EP2654783B1 (de) * 2010-12-21 2016-10-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante mycobacterium als impfstoff
EP2838990A4 (de) * 2012-04-16 2016-08-10 Aeras Global Tb Vaccine Found Rekombinantes mycobakterium zur codierung eines heparin-bindenden hämagglutinin (hbha)-fusionsproteins und verwendungen davon
CN102732480A (zh) * 2012-06-11 2012-10-17 中山大学 N-乙酰半胱氨酸对中央记忆性t细胞的绝对数量在体外扩增上的应用
CN118662620A (zh) * 2023-03-15 2024-09-20 康希诺生物股份公司 一种肺结核疫苗及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
CA2467486A1 (en) * 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine

Also Published As

Publication number Publication date
US7850979B2 (en) 2010-12-14
UA93665C2 (ru) 2011-03-10
CN102580070A (zh) 2012-07-18
RS51815B (sr) 2011-12-31
CN101115500A (zh) 2008-01-30
DE602006020679D1 (de) 2011-04-28
ES2364698T3 (es) 2011-09-12
DK1833507T3 (da) 2011-07-11
PT1833507E (pt) 2011-06-27
GB0500102D0 (en) 2005-02-09
ZA200706389B (en) 2008-08-27
US20080226678A1 (en) 2008-09-18
SI1833507T1 (sl) 2011-07-29

Similar Documents

Publication Publication Date Title
Chavda et al. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era
Khan DNA vaccines: roles against diseases
Delany et al. Vaccines for the 21st century
da Costa et al. Tuberculosis vaccines–state of the art, and novel approaches to vaccine development
Ottenhoff et al. Vaccines against tuberculosis: where are we and where do we need to go?
Brockstedt et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity
Khallouf et al. Therapeutic vaccine strategies against human papillomavirus
Nel et al. Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape
Moser et al. Influenza virosomes as a vaccine adjuvant and carrier system
Zheng et al. Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in vaccine development and tumor immunotherapy
CY1111549T1 (el) Συνθεσεις για ανοσοποιηση εναντι μυκοβακτηριδιου
Bridle et al. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines
Roohvand et al. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities
ZA200706389B (en) Compositions for immunizing against mycobacterium
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
Behar et al. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells
Gillis et al. rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B
Kwon et al. BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice
Villarreal et al. Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG
Hu et al. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines
Iurescia et al. Strategies for improving DNA vaccine performance
Wan et al. As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity-and IL-6-dependent manner
Stanberry et al. Vaccines of the future

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1833507

Country of ref document: EP